Logo image of AQST

AQUESTIVE THERAPEUTICS INC (AQST) Stock Fundamental Analysis

NASDAQ:AQST - Nasdaq - US03843E1047 - Common Stock - Currency: USD

2.87  +0.02 (+0.7%)

After market: 2.9 +0.03 (+1.05%)

Fundamental Rating

2

AQST gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 199 industry peers in the Pharmaceuticals industry. AQST has a bad profitability rating. Also its financial health evaluation is rather negative. AQST is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AQST had negative earnings in the past year.
In the past year AQST has reported a negative cash flow from operations.
In the past 5 years AQST always reported negative net income.
AQST had a negative operating cash flow in each of the past 5 years.
AQST Yearly Net Income VS EBIT VS OCF VS FCFAQST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

AQST has a Return On Assets (-43.52%) which is in line with its industry peers.
Industry RankSector Rank
ROA -43.52%
ROE N/A
ROIC N/A
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AQST Yearly ROA, ROE, ROICAQST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

Looking at the Gross Margin, with a value of 68.95%, AQST is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
In the last couple of years the Gross Margin of AQST has grown nicely.
AQST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
AQST Yearly Profit, Operating, Gross MarginsAQST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

AQST does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AQST has more shares outstanding
AQST has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AQST has an improved debt to assets ratio.
AQST Yearly Shares OutstandingAQST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AQST Yearly Total Debt VS Total AssetsAQST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

AQST has an Altman-Z score of -3.57. This is a bad value and indicates that AQST is not financially healthy and even has some risk of bankruptcy.
AQST has a Altman-Z score of -3.57. This is comparable to the rest of the industry: AQST outperforms 41.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.57
ROIC/WACCN/A
WACC10.85%
AQST Yearly LT Debt VS Equity VS FCFAQST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

AQST has a Current Ratio of 4.68. This indicates that AQST is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.68, AQST is in the better half of the industry, outperforming 70.85% of the companies in the same industry.
A Quick Ratio of 4.36 indicates that AQST has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.36, AQST is doing good in the industry, outperforming 68.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.68
Quick Ratio 4.36
AQST Yearly Current Assets VS Current LiabilitesAQST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

AQST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -44.44%.
Looking at the last year, AQST shows a quite strong growth in Revenue. The Revenue has grown by 13.81% in the last year.
The Revenue has been growing slightly by 1.82% on average over the past years.
EPS 1Y (TTM)-44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)13.81%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-2.15%

3.2 Future

The Earnings Per Share is expected to grow by 24.25% on average over the next years. This is a very strong growth
AQST is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.98% yearly.
EPS Next Y-31.42%
EPS Next 2Y-5.18%
EPS Next 3Y11.65%
EPS Next 5Y24.25%
Revenue Next Year-15.55%
Revenue Next 2Y8.54%
Revenue Next 3Y20.36%
Revenue Next 5Y33.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AQST Yearly Revenue VS EstimatesAQST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
AQST Yearly EPS VS EstimatesAQST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AQST. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AQST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQST Price Earnings VS Forward Price EarningsAQST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQST Per share dataAQST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.18%
EPS Next 3Y11.65%

More info and screens

0

5. Dividend

5.1 Amount

AQST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AQUESTIVE THERAPEUTICS INC

NASDAQ:AQST (4/25/2025, 8:00:00 PM)

After market: 2.9 +0.03 (+1.05%)

2.87

+0.02 (+0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-05 2025-03-05/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners51.75%
Inst Owner Change-58.18%
Ins Owners5.23%
Ins Owner Change13.39%
Market Cap283.76M
Analysts84
Price Target10.06 (250.52%)
Short Float %10.78%
Short Ratio6.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.94%
Min EPS beat(2)-37.26%
Max EPS beat(2)-0.62%
EPS beat(4)1
Avg EPS beat(4)-16.01%
Min EPS beat(4)-102.44%
Max EPS beat(4)76.28%
EPS beat(8)4
Avg EPS beat(8)3.73%
EPS beat(12)8
Avg EPS beat(12)7.08%
EPS beat(16)12
Avg EPS beat(16)9.78%
Revenue beat(2)1
Avg Revenue beat(2)-7.34%
Min Revenue beat(2)-19.36%
Max Revenue beat(2)4.68%
Revenue beat(4)2
Avg Revenue beat(4)10.21%
Min Revenue beat(4)-19.36%
Max Revenue beat(4)59.16%
Revenue beat(8)4
Avg Revenue beat(8)7.3%
Revenue beat(12)8
Avg Revenue beat(12)8.56%
Revenue beat(16)12
Avg Revenue beat(16)13.59%
PT rev (1m)-8.97%
PT rev (3m)-8.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30.77%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.5%
Revenue NY rev (1m)-6.33%
Revenue NY rev (3m)-6.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.93
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0.58
BVpS-0.61
TBVpS-0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.52%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.95%
FCFM N/A
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
F-Score4
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.14%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.68
Quick Ratio 4.36
Altman-Z -3.57
F-Score4
WACC10.85%
ROIC/WACCN/A
Cap/Depr(3y)67.19%
Cap/Depr(5y)49.48%
Cap/Sales(3y)2.51%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y-31.42%
EPS Next 2Y-5.18%
EPS Next 3Y11.65%
EPS Next 5Y24.25%
Revenue 1Y (TTM)13.81%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-2.15%
Revenue Next Year-15.55%
Revenue Next 2Y8.54%
Revenue Next 3Y20.36%
Revenue Next 5Y33.98%
EBIT growth 1Y-103.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-85.72%
EBIT Next 3Y41.74%
EBIT Next 5Y41.02%
FCF growth 1Y-387.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-460.49%
OCF growth 3YN/A
OCF growth 5YN/A